Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000296636 | SCV000339801 | uncertain significance | not provided | 2016-03-30 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000763896 | SCV000894831 | uncertain significance | Fraser syndrome 2 | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000296636 | SCV003784478 | uncertain significance | not provided | 2022-04-10 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 13 of the FREM2 protein (p.Arg13Gln). This variant is present in population databases (rs765718616, gnomAD 0.04%), including at least one homozygous and/or hemizygous individual. This variant has not been reported in the literature in individuals affected with FREM2-related conditions. ClinVar contains an entry for this variant (Variation ID: 286386). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |